Based on the facts that mutp53 is frequently accumulated to very higher levels in tumor tissues, loses transcriptional activity of wild-type p53, and frequently acquires GOF activities through interacting with other proteins and/or regulating critical downstream signaling pathways, different strategies have been developed to target mutp53 for cancer therapy. The gene discussed is TP53; the disease is cancer.